Normal and leukaemic stem cells.
The blood-related cancer leukaemias were the first diseases where human cancer stem cells, or leukaemic stem cells (LSC), were isolated. The haematopoietic system is one of the best tissues for investigating cancer stem cells, because the developmental hierarchy of normal blood formation is well defined. Leukaemias can now be viewed as aberrant haematopoietic processes initiated by rare LSC that have maintained or reacquired the capacity for indefinite proliferation through accumulated mutations and/or epigenetic changes. Yet, despite their critical importance, much remains to be learned about the developmental origin of LSC and the mechanisms responsible for their emergence in the course of the disease. This report will review our current knowledge on normal and LSC development and examine the impact of these discoveries may have clinically and in our understanding of the leukaemogenic process.
Bonnet
Dominique
D
Haematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute, London, UK. dominique.bonnet@cancer.org.uk
D000208:Acute Disease; D002453:Cell Cycle; D019070:Cell Lineage; D015972:Gene Expression Regulation, Neoplastic; D005801:Genes, Homeobox; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology; D007951:Leukemia, Myeloid / Q000473:pathology*; D009154:Mutation; D014411:Neoplastic Stem Cells / Q000473:pathology*